Canadian Neurological Sciences Federation The Canadian Journal of Neurological Sciences is the official publication of the four member societies of the Canadian Neurological Sciences Federation -- Canadian Neurological Society (CNS), Canadian Association of Child Neurology (CACN), Canadian Neurosurgical Society (CNSS), Canadian Society of Clinical Neurophysiologists (CSCN). The Journal is a widely circulated internationally recognized medical journal that publishes peer-reviewed articles. The Journal is published in January, March, May, July, September, and November in an online only format. The first Canadian Journal of Neurological Sciences (the Journal) was published in 1974 in Winnipeg. In 1981, the Journal became the official publication of the member societies of the CNSF.
加拿大神经科学联合会《加拿大神经科学杂志》是加拿大神经科学联合会四个成员学会的官方出版物--加拿大神经学会(CNS)、加拿大儿童神经病学协会(CACN)、加拿大神经外科学会(CNSS)、加拿大临床神经生理学家学会(CSCN)。该杂志是一个广泛发行的国际公认的医学杂志,发表同行评审的文章。该期刊于1月、3月、5月、7月、9月和11月以在线形式出版。第一本加拿大神经科学杂志(The Journal of Neurological Sciences)于1974年在温尼伯出版。1981年,该杂志成为CNSF成员学会的官方出版物。
年发文量 104
国人发稿量 2.4
国人发文占比 0.02%
自引率 -
平均录取率0
平均审稿周期 偏慢,4-8周
版面费 US$2205
偏重研究方向 医学-临床神经学
期刊官网 http://www.cnsfederation.org/cnsf/cjns/
投稿链接 https://mc.manuscriptcentral.com/cjn
期刊高被引文献
A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I
来源期刊:Canadian Journal of Neurological SciencesDOI:10.1017/cjn.2019.89
P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study
来源期刊:Canadian Journal of Neurological SciencesDOI:10.1017/cjn.2019.124
GP.01 Childhood obesity and multiple sclerosis susceptibility: a Mendelian randomization study
来源期刊:Canadian Journal of Neurological SciencesDOI:10.1017/cjn.2019.77
Stereologic measures of beta-amyloid load in postmortem autosomal dominant Alzheimer disease brain validate PiB-PET as a useful biomarker
来源期刊:Canadian Journal of Neurological SciencesDOI:10.1017/cjn.2019.257
P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement
来源期刊:Canadian Journal of Neurological SciencesDOI:10.1017/cjn.2019.125
Non-Perfused Brain and Retino-Dural Hemorrhage
来源期刊:Canadian Journal of Neurological SciencesDOI:10.1017/cjn.2019.260